AP reports agency scientists did not back the administration's effort to loosen rules on peptide drugs that remain unproven.
Recap by typeshit. Full story at Associated Press News.
STAT
The temporary enforcement discretion covers six peptides an FDA advisory committee recommended in July. STAT notes there is little evidence for many of these wellness compounds.
A US judge turned down Novo's request to halt Lilly's Zepbound advertising while the false advertising dispute continues.
STAT
STAT's Pharmalittle notes Catherine Hanaway says Lilly broke its promise on discounted drugs to hospitals, alongside new results for a Lilly weight loss drug.
STAT notes RFK Jr. and the MAHA movement have embraced peptides, though evidence for many of these wellness compounds is thin. A July FDA panel backed all six.
Lilly says both retatrutide doses cut HbA1c by 2.2% versus 1.8% for semaglutide 2mg at week 80, with more than double the weight loss, across 1,298 adults.
Lilly says the 12 mg dose cut weight 21% versus 9% on Ozempic over 80 weeks, though 8% quit over side effects compared with 3% on Novo's drug.
Loading…